ライフサイエンスコーパス: aminolevulinic acid

1 ides 2.4.1 which catalyze the formation of 5-aminolevulinic acid.

2 catalyzed condensation of two molecules of 5-aminolevulinic acid.

3 peptide-based photodynamic therapy agent, 5-aminolevulinic acid.

4 , which was intensified by pretreatment with aminolevulinic acid.

5 applying protoporphyrin IX or its precursor aminolevulinic acid.

6 nsed with succinyl coenzyme A to yield delta-aminolevulinic acid.

7 linically approved PSs porfimer sodium and 5-aminolevulinic acid.

8 of amplifying endogenous heme synthesis with aminolevulinic acid.

9 xpress rabbit GAPDH in the presence of delta-aminolevulinic acid.

10 tachlorbiphenyl, an inducer of CYP1A2, and 5-aminolevulinic acid.

11 d heme b when expressed in the presence of 5-aminolevulinic acid.

12 luorinated analog of 5-ALA, i.e., 3-fluoro-5-aminolevulinic acid (3F-5-ALA).

13 ic labeling with [2-14C]glycine or delta-[3H]aminolevulinic acid ([3H]ALA) was used to investigate he

14 ale production of the FDA-approved prodrug 5-aminolevulinic acid (5-ALA) and the late-stage functiona

15 Cells were incubated with PpIX pro-drug 5-aminolevulinic acid (5-ALA) at 0, 1, 2, 3, and 4 mM for

16 All patients received 5-aminolevulinic acid (5-ALA) fluorescence guidance surger

17 eriority of intraoperative MRI (iMRI) over 5-aminolevulinic acid (5-ALA) for achieving complete resec

18 In 2017, the FDA authorized 5-aminolevulinic acid (5-ALA) for intraoperative optical i

19 Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) is now a widely-used modalit

20 (PpIX), which is endogenously derived from 5-aminolevulinic acid (5-ALA) or its derivatives, is a pro

21 A novel 5-aminolevulinic acid (5-ALA) prodrug was custom-designed

22 Systemic administration of 5-aminolevulinic acid (5-ALA) results in accumulation of t

23 5-aminolevulinic acid (5-ALA) was injected at a dose of 60

24 delta-Aminolevulinic acid (5-ALA) was used to induce apoptosis

25 thway, and cancer cells accumulate it when 5-aminolevulinic acid (5-ALA), a precursor, is administere

26 d fluorophore in glioma-resection surgery, 5-aminolevulinic acid (5-ALA), is thought to cause the sel

27 croneedles for improved dermal delivery of 5-aminolevulinic acid (5-ALA), which naturally gets conver

28 cal, oral, or parenteral administration of 5-aminolevulinic acid, a precursor for heme biosynthesis.

29 us studies revealed periodic fluctuations of aminolevulinic acid, a precursor of heme, indicating tha

30 r deferoxamine and the porphyrin precursor 5-aminolevulinic acid (ALA) (mimicking intracellular proto

31 During AIP, delta-aminolevulinic acid (ALA) accumulates and promotes tubul

32 5-aminolevulinic acid (ALA) and carnosine have important p

33 In mice treated with 5-aminolevulinic acid (ALA) and polyhalogenated aromatic c

34 nts comprised clinical AHP features, urinary aminolevulinic acid (ALA) and porphobilinogen (PBG) leve

35 constitutively elevated plasma and urinary 5-aminolevulinic acid (ALA) and porphobilinogen (PBG), pro

36 B-synthase activities and elevated urinary 5-aminolevulinic acid (ALA) and porphobilinogen (PBG), the

37 ion of the neurotoxic porphyrin precursors 5-aminolevulinic acid (ALA) and porphobilinogen (PBG), whi

38 s oligopeptides and the heme precursor delta-aminolevulinic acid (ALA) by a common mechanism.

39 delta-Aminolevulinic acid (ALA) causes cells to accumulate pro

40 dy, we investigated whether the amino acid 5-aminolevulinic acid (ALA) could sensitize glioma stem ce

41 Addition of delta-aminolevulinic acid (ALA) in darkness drastically increa

42 ubations arms, either 10-minute or 20-minute aminolevulinic acid (ALA) incubation times, after pretre

43 The tetrapyrrole precursor 5-aminolevulinic acid (ALA) inhibited Lhcb expression in h

44 hydratase (ALAD), an enzyme converting delta-aminolevulinic acid (ALA) into porphobilinogen.

45 The synthesis of 5-aminolevulinic acid (ALA) is a key regulatory step for t

46 5-aminolevulinic acid (ALA) is a precursor in the biosynth

47 Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is based upon the intracellula

48 cteria, the heme and chlorophyll precursor 5-aminolevulinic acid (ALA) is formed from glutamate in a

49 Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is increasingly employed for s

50 The heme precursor delta-aminolevulinic acid (ALA) is taken up by the dipeptide p

51 In plants, 5-aminolevulinic acid (ALA) is the common precursor of tet

52 5-Aminolevulinic acid (ALA) is the first committed substra

53 5-Aminolevulinic acid (ALA) is the first committed univers

54 The synthesis of 5-aminolevulinic acid (ALA) is the rate-limiting step for

55 Synthesis of 5-aminolevulinic acid (ALA) is the rate-limiting step in t

56 5-Aminolevulinic acid (ALA) is the universal precursor of

57 utants defective in the genes encoding delta-aminolevulinic acid (ALA) synthase and ferrochelatase, e

58 nscripts for the two committed enzymes for 5-aminolevulinic acid (ALA) synthesis despite the marked i

59 By grafting 5-aminolevulinic acid (ALA) to a Hf(12) -based nanoscale m

60 symmetric condensation of two molecules of 5-aminolevulinic acid (ALA) to form porphobilinogen.

61 ollowing photosensitization by administering aminolevulinic acid (ALA) to induce the accumulation of

62 increased ability to convert the precursor 5-aminolevulinic acid (ALA) to PPIX appeared to reinforce

63 of regulated heme synthesis was achieved by aminolevulinic acid (ALA) treatment of mice or cultured

64 When [14N]aminolevulinic acid (ALA) was supplemented to 15N-BG-11

65 lyzes the condensation of two molecules of 5-aminolevulinic acid (ALA), an essential step in tetrapyr

66 e common precursor to all tetrapyrroles is 5-aminolevulinic acid (ALA), and in Rhodobacter sphaeroide

67 synthesize the tetrapyrrole precursor, delta-aminolevulinic acid (ALA), from glutamate by means of a

68 ith the first committed heme precursor alpha-aminolevulinic acid (ALA), generates high levels of PP-I

69 ies to help clarify the roles of heme, delta-aminolevulinic acid (ALA), hemA, and hemM in Escherichia

70 es can be potently stimulated by exogenous 5-aminolevulinic acid (ALA), resulting in accumulation of

71 Metabolomic analysis revealed that 5-aminolevulinic acid (ALA), the first heme precursor, is

72 an FDA-approved human precursor molecule, 5-aminolevulinic acid (ALA), to stimulate a unique delayed

73 ion of porphyrin precursors, in particular 5-aminolevulinic acid (ALA), which is thought to be the ne

74 ice in a 129S6/SvEvTac background were fed 5-aminolevulinic acid (ALA), which results in hepatic URO

75 re, we investigated the in vivo effects of 5-aminolevulinic acid (ALA)-mediated SDT on early-stage mu

76 ed with increased urinary excretion of delta-aminolevulinic acid (ALA).

77 symmetric condensation of two molecules of 5-aminolevulinic acid (ALA).

78 IX (PPIX), can be enhanced in the cells by 5-aminolevulinic acid (ALA).

79 m the universal tetrapyrrole precursor delta-aminolevulinic acid (ALA).

80 C) cells after treatment with PpIX precursor aminolevulinic acid (ALA).

81 herapy, mediated by exogenously administered aminolevulinic acid (ALA-PDT), followed by exposure to a

82 Fluorescence guided surgery (FGS) using aminolevulinic-acid (ALA) induced protoporphyrin IX (PpI

83 the movement of 5-aminolevulinic acid (delta-aminolevulinic acid; ALA) between blood and brain.

84 tes with aminolevulinic acid plus red light, aminolevulinic acid alone, light alone, and untreated co

85 been shown to have higher specificity than 5-aminolevulinic acid and can possibly play a complementar

86 ifests a defect in the biosynthesis of delta-aminolevulinic acid and displays reduced levels of downs

87 Fluorescence cystoscopy with 5-aminolevulinic acid and hexaminolevulinate has been show

88 en approved for systemic administration, and aminolevulinic acid and methyl aminolevulinate have been

89 ydratase deficient porphyria) or increased 5-aminolevulinic acid and porphobilinogen (in patients wit

90 levels of the neurotoxic intermediates delta aminolevulinic acid and porphobilinogen, and a lower att

91 caused by restriction on the formation of 5-aminolevulinic acid and protochlorophyllide.

92 utant has a reduced capacity to synthesize 5-aminolevulinic acid and reduced CHLM activity compared w

93 sion and magnitude of expression of GAPDH, d-aminolevulinic acid, and FLVCR1b.

94 PCT: wild-type mice treated with iron, delta-aminolevulinic acid, and polychlorinated biphenyls; and

95 e 1 messenger ribonucleic acid levels, delta-aminolevulinic acid, and porphobilinogen compared with t

96 uctions in ALAS1 messenger RNA (mRNA), delta aminolevulinic acid, and porphobilinogen levels to near

97 ation into heme from its precursor 5-[(13)C4]aminolevulinic acid, and this assay confirmed that de no

98 antitative measurement of porphobilinogen, 5-aminolevulinic acid, and total porphyrin levels.

99 27, and contributes to feedback-control of 5-aminolevulinic acid biosynthesis, the rate-limiting step

100 d, unexpectedly, that it is the enzyme delta-aminolevulinic acid dehydratase (ALA-D) and that it does

101 ALAD gene (chromosome 9q34) codes for delta-aminolevulinic acid dehydratase (ALAD) (E.C. 4.2.1.24).

102 encoding the haem biosynthesis enzyme delta-aminolevulinic acid dehydratase (ALAD) is normally repre

103 ms and its potential modification by a delta-aminolevulinic acid dehydratase (ALAD) polymorphism.

104 The heme biosynthesis enzyme delta-aminolevulinic acid dehydratase (ALAD) requires magnesiu

105 We report a new assay of human delta-aminolevulinic acid dehydratase (ALAD), an enzyme conver

106 endent transcriptional co-regulator of delta-aminolevulinic acid dehydratase (Alad), but not 5-aminol

107 wo pathways through our discovery that human aminolevulinic acid dehydratase (ALAD), which catalyzes

108 /g w/w), and those birds exhibited reduced d-aminolevulinic acid dehydratase activity, indicating a b

109 te porphyria, hereditary coproporphyria, and aminolevulinic acid dehydratase deficient porphyria) man

110 nary 5-aminolevulinic acid (in patients with aminolevulinic acid dehydratase deficient porphyria) or

111 TX)), and the K59N polymorphism in the delta-aminolevulinic acid dehydratase gene, ALAD, were measure

112 d for use in the clinical diagnosis of delta-aminolevulinic acid dehydratase-deficient porphyria, a r

113 ene encoding the heme synthesis enzyme delta-aminolevulinic acid dehydratase.

114 bition of the heme biosynthetic enzyme delta-aminolevulinic acid dehydratase.

115 on is modified by polymorphisms in the delta-aminolevulinic acid dehydrogenase (ALAD) gene.

116 in and cefadroxil, the antineoplastics delta-aminolevulinic acid (delta-ALA) and bestatin, and the ne

117 y of UVA alone and in combination with delta-aminolevulinic acid (delta-ALA), a precursor of the intr

118 Little is known about the movement of 5-aminolevulinic acid (delta-aminolevulinic acid; ALA) bet

119 oplasts by feeding these chloroplasts with 5-aminolevulinic acid, determined the relative levels of G

120 , the rate-limiting enzyme upstream of delta-aminolevulinic acid export, failed to restore heme level

121 delta-Aminolevulinic acid-fed antisense Arabidopsis plants wit

122 Our results indicate that 5-aminolevulinic acid feeding stimulates Mg-chelatase acti

123 trongly accumulates in mutant leaves after 5-aminolevulinic acid feeding.

124 classified according to micro-cystoscopic 5-aminolevulinic acid fluorescence diagnosis, and specimen

125 an and given drinking water containing delta-aminolevulinic acid for 21 days, hepatic porphyrins accu

126 an but not rat liver, maximal rates of delta-aminolevulinic acid formation required addition to the i

127 ore assay did not increase the rate of delta-aminolevulinic acid formation.

128 e-cell biotransformation to the synthesis of aminolevulinic acid from a lignin-derived feedstock.

129 plication of the photosensitizer precursor 5-aminolevulinic acid has therapeutic implications for the

130 fter 3 h of incubation in the heme precursor aminolevulinic acid hexylester, EMT6 cells accumulated a

131 LECTION Only randomized PDT trials that used aminolevulinic acid hydrochloride ormethyl aminolevulina

132 al use of the combination of tellurite and 5-aminolevulinic acid in antimicrobial therapy.

133 relies on measurement of increased urinary 5-aminolevulinic acid (in patients with aminolevulinic aci

134 orphyrin precursors, porphobilinogen, and/or aminolevulinic acid, in the blood.

135 Although delta-[(14)C]aminolevulinic acid incorporation demonstrated formation

136 zoporphyrin derivative monoacid ring A and 5-aminolevulinic acid-induced protoporphyrin IX, were stud

137 as show the direct in vitro conversion of 5-aminolevulinic acid into cobyrinic acid using a mixture

138 2) The incorporation of radioactive delta-aminolevulinic acid into heme A is reduced in yah1 ts bu

139 Hexyl-5-aminolevulinic acid is an ester form of 5-aminolevulinic

140 Topical aminolevulinic acid is converted into a potent photosens

141 eased synthesis of glutamate semialdehyde, 5-aminolevulinic acid, magnesium-porphyrins, and chlorophy

142 he carrier's physiological ligand, whereas 5-aminolevulinic acid makes far fewer interactions compare

143 photodynamic therapy using topical methyl 5-aminolevulinic acid (MAL) for actinic keratoses (AKs) is

144 respond adequately to PDT with methyl-delta-aminolevulinic acid (MAL-PDT) and the tumors acquire an

145 With this model, we demonstrated that 5-aminolevulinic acid-mediated sonodynamic therapy (ALA-SD

146 by favoring low-activity oligomers, while 5-aminolevulinic acid, Mg(2+), or K(+) stabilized high-act

147 oxybenzoic acid (3,4-AHBA), and a cyclized 5-aminolevulinic acid moiety, 2-amino-3-hydroxycyclopent-2

148 loenzyme catalyzes the condensation of two 5-aminolevulinic acid molecules to form the tetrapyrrole p

149 hylnicotinamide, 3-hydroxyisovaleric acid, 5-aminolevulinic acid, N-acetylglutamine and methanol-whic

150 ad activity peak (pH 7-8.5), with a K(m) for aminolevulinic acid of approximately 150 microM and spec

151 nin contents and de-represses synthesis of 5-aminolevulinic acid of tetrapyrrole metabolism in darkne

152 Pretreatment with aminolevulinic acid or with protoporphyrin IX dramatical

153 nd underwent a second cycle of curettage and aminolevulinic acid PDT with resolution.

154 protocol that included curettage followed by aminolevulinic acid PDT.

155 was successfully retreated with curettage + aminolevulinic acid PDT.

156 ge of the hyperkeratotic lesions followed by aminolevulinic acid photodynamic therapy (PDT) 1 to 2 we

157 e skin inflammation occurs following topical aminolevulinic acid-photodynamic therapy (ALA-PDT), but

158 Aminolevulinic acid plus red light caused a transient ac

159 Aminolevulinic acid plus red light causes phototoxicity

160 Topical aminolevulinic acid plus red light is an effective treat

161 Potentially, aminolevulinic acid plus red light may be useful for som

162 e on the back was treated in four sites with aminolevulinic acid plus red light, aminolevulinic acid

163 ignificant clearance of inflammatory acne by aminolevulinic acid plus red light, for at least 20 wk a

164 heme synthesis pathway by facilitating delta-aminolevulinic acid production or export from the mitoch

165 Irradiation of aminolevulinic acid/protoporphyrin IX-sensitized cells w

166 nt of tumor-specific fluorophores, such as 5-aminolevulinic acid, real-time microscopic visualization

167 Addition of the heme precursor delta-aminolevulinic acid restored the cytochrome content, res

168 proteins, whereas supplementation with delta-aminolevulinic acid reversed these defects.

169 Aminolevulinic acid synthase (ALAS) initiates heme biosy

170 e initiating enzyme for heme biosynthesis, 5-aminolevulinic acid synthase (ALAS), by promoting cofact

171 5-Aminolevulinic acid synthase (ALAS-1) is the first rate

172 d enzymatic assays indicate that erythroid 5-aminolevulinic acid synthase (Alas2) is decreased in hem

173 mRNA levels for globin and erythroid aminolevulinic acid synthase (eALAS) were the same in bo

174 to a deletion in the gene that encodes delta-aminolevulinic acid synthase (HEM1), resulted in decreas

175 Induction of delta aminolevulinic acid synthase 1 ( ALAS1) gene expression

176 pitated by factors that upregulate hepatic 5-aminolevulinic acid synthase 1 (ALAS1) activity.

177 tors that induce the expression of hepatic 5-aminolevulinic acid synthase 1 (ALAS1) result in the acc

178 In this work, we uncover 5-aminolevulinic acid synthase 1 (ALAS1), the initiating e

179 Elevated levels of hepatic delta-aminolevulinic acid synthase 1 messenger ribonucleic aci

180 duction begins with the rate-limiting enzyme aminolevulinic acid synthase 2 (ALAS2) in the mitochondr

181 Marked overexpression of 5-aminolevulinic acid synthase 2 (Alas2) results from loss

182 ate-limiting enzyme in heme synthesis, delta-aminolevulinic acid synthase 2 (ALAS2), was significantl

183 ermediate porphyrins and decreased levels of aminolevulinic acid synthase 2 activity.

184 lastic anemia (XLSA) in female carriers of 5-aminolevulinic acid synthase 2 mutations is not uncommon

185 but results from increased activity of delta-aminolevulinic acid synthase 2, the first step in heme b

186 Overexpression of mitochondrial delta-aminolevulinic acid synthase 2, the rate-limiting enzyme

187 These knock-out parasite lines, lacking 5-aminolevulinic acid synthase and/or ferrochelatase (FC),

188 Mutations in the erythroid-specific aminolevulinic acid synthase gene (ALAS2) cause X-linked

189 whereby increased cellular heme regulates 5-aminolevulinic acid synthase is by decreasing the stabil

190 nase, and heme (200 nM); (c) Repression of 5-aminolevulinic acid synthase mRNA levels by zinc mesopor

191 a decrease in cellular heme might increase 5-aminolevulinic acid synthase mRNA stability and whether

192 We found that: (a) The stability of 5-aminolevulinic acid synthase mRNA was markedly increased

193 eroxamine; (b) This increased stability of 5-aminolevulinic acid synthase mRNA was reversed by the ad

194 mium mesoporphyrin significantly decreased 5-aminolevulinic acid synthase mRNA without increasing hem

195 heme-like, effect of zinc mesoporphyrin on 5-aminolevulinic acid synthase mRNA; (d) Among the several

196 Hepatic 5-aminolevulinic acid synthase, the first and normally rat

197 5-Aminolevulinic acid synthesis rates are increased and co

198 In conjunction with the dark repression of 5-aminolevulinic acid synthesis, GUN4 phosphorylation mini

199 codes for one of two isoenzymes catalyzing 5-aminolevulinic acid synthesis.

200 ns, respectively, in the erythroid form of 5-aminolevulinic acid synthetase (ALAS), ALAS2, which enco

201 y of low levels of activity of hepatic delta-aminolevulinic acid synthetase have been studied, compar

202 yl-CoA generation was more labile than delta-aminolevulinic acid synthetase under these conditions.

203 delta-Aminolevulinic acid, the biosynthetic precursor of tetra

204 de isozymes that catalyze the formation of 5-aminolevulinic acid, the first step in the biosynthesis

205 ness for 14 days, upon the addition of delta-aminolevulinic acid, the level of magnesium-protoporphyr

206 hlorophyll share common intermediates from 5-aminolevulinic acid through protoporphyrin IX.

207 ALA-D is about as active in converting delta-aminolevulinic acid to porphobilinogen and as Zn2+-depen

208 We conjugated the photosensitizer 5-aminolevulinic acid to the lipophilic cation triphenylph

209 Twenty percent topical aminolevulinic acid was applied with 3 h occlusion, and

210 eviously, topical PDT using blue light and 5-aminolevulinic acid was found to be a potent stimulus fo

211 Photodynamic therapy with topical aminolevulinic acid was tested for the treatment of acne

212 rthermore, we show that the heme precursor 5-aminolevulinic acid, which is used as an antimicrobial a

213 -5-aminolevulinic acid is an ester form of 5-aminolevulinic acid with improved uptake by tumor cells.